Ginkgo announces strategic partnership with Inductive Bio and Tangible

Ginkgo Bioworks (DNA) announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry. The partnership aims to deliver capabilities that previously required massive platform investments by combining high-throughput experimental workflows, streamlined compound management, and predictive chemistry AI models into a seamless integrated service that could help scientists design better drugs with fewer resources. The new collaboration connects three core capabilities: Ginkgo Datapoints’ rapid ADME profiling, Inductive Bio’s model-driven chemistry design platform, and Tangible Scientific’s API-enabled compound management platform. Together, these capabilities aim to move from in-silico compound designs to validated experimental results in one digitally-enabled workstream, with fewer synthesis cycles, faster turnarounds, and lower overall drug discovery costs. The services are available now and are tailored for pharmaceutical and biotech teams looking to improve ADMET optimization and reduce iteration times on programs and across portfolios.